Related Experiment Video
Updated: May 12, 2026

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
Published on: January 31, 2013
Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice
Renzhi Han1, Ellie M Frett, Jennifer R Levy
1Howard Hughes Medical Institute, Department of Molecular Physiology and Biophysics, Department of Neurology, Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.
Abstract:
Mutations in the dysferlin gene underlie a group of autosomal recessive muscle-wasting disorders denoted as dysferlinopathies. Dysferlin has been shown to play roles in muscle membrane repair and muscle regeneration, both of which require vesicle-membrane fusion. However, the mechanism by which muscle becomes dystrophic in these disorders remains poorly understood. Although muscle inflammation is widely recognized in dysferlinopathy and dysferlin is expressed in immune cells, the contribution of the immune system to the pathology of dysferlinopathy remains to be fully explored. Here, we show that the complement system plays an important role in muscle pathology in dysferlinopathy. Dysferlin deficiency led to increased expression of complement factors in muscle, while muscle-specific transgenic expression of dysferlin normalized the expression of complement factors and eliminated the dystrophic phenotype present in dysferlin-null mice. Furthermore, genetic disruption of the central component (C3) of the complement system ameliorated muscle pathology in dysferlin-deficient mice but had no significant beneficial effect in a genetically distinct model of muscular dystrophy, mdx mice. These results demonstrate that complement-mediated muscle injury is central to the pathogenesis of dysferlinopathy and suggest that targeting the complement system might serve as a therapeutic approach for this disease.
Insights
Dysferlin deficiency causes muscle wasting by activating the complement system. Targeting this system ameliorates muscle pathology in dysferlinopathy, offering a potential therapeutic strategy.
Area of Science:
- Muscle biology
- Immunology
- Genetics
Background:
- Mutations in the dysferlin gene cause dysferlinopathies, a group of muscle-wasting disorders.
- Dysferlin is crucial for muscle membrane repair and regeneration, involving vesicle-membrane fusion.
- The immune system's role in dysferlinopathy pathogenesis is not fully understood.
Purpose of the Study:
- To investigate the role of the complement system in the muscle pathology of dysferlinopathies.
- To explore the potential of targeting the complement system as a therapeutic strategy for dysferlinopathy.
Main Methods:
- Analyzing complement factor expression in dysferlin-deficient mice.
- Examining the effects of muscle-specific dysferlin expression on complement factors and muscle phenotype.
- Assessing the impact of complement component 3 (C3) disruption on muscle pathology in dysferlin-deficient and mdx mice.
Main Results:
- Dysferlin deficiency led to increased complement factor expression in muscles.
- Restoring dysferlin expression normalized complement factors and resolved the dystrophic phenotype in mice.
- Genetic disruption of C3 ameliorated muscle pathology in dysferlin-deficient mice but not in mdx mice.
Conclusions:
- Complement-mediated muscle injury is central to dysferlinopathy pathogenesis.
- Targeting the complement system represents a promising therapeutic avenue for dysferlinopathies.

